Eagle Pharmaceuticals Operating Income 2013-2023 | EGRX

Eagle Pharmaceuticals operating income from 2013 to 2023. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.

Eagle Pharmaceuticals Operating Income 2013-2023 | EGRX

Eagle Pharmaceuticals operating income from 2013 to 2023. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Related Stocks
Company NameMarket
Cap
Abbott Laboratories (ABT)$196.7B
Stryker (SYK)$142.8B
Boston Scientific (BSX)$132.8B
EssilorLuxottica (ESLOY)$110.9B
Medtronic (MDT)$105.8B
Haleon (HLN)$44.2B
Lonza Group Ag (LZAGY)$43.1B
GE HealthCare Technologies (GEHC)$37.1B
ResMed (RMD)$35B
Terumo (TRUMY)$29.6B
Koninklijke Philips (PHG)$24.2B
Zimmer Biomet Holdings (ZBH)$21.2B
Insulet (PODD)$18.9B
Baxter (BAX)$15.5B
Smith & Nephew SNATS (SNN)$11.2B
BellRing Brands (BRBR)$10B
Bio-Rad Laboratories (BIO)$9.4B
Demant (WILYY)$8.3B
Lantheus Holdings (LNTH)$6.5B
Haemonetics (HAE)$4.1B
Prestige Consumer Healthcare (PBH)$4.1B
ICU Medical (ICUI)$4B
Perrigo (PRGO)$3.7B
Envista Holdings (NVST)$3.4B
Shandong Weigao Medical Polymer (SHWGF)$3B
GN Store Nord (GNNDY)$2.9B
QuidelOrtho (QDEL)$2.8B
Neogen (NEOG)$2.6B
LeMaitre Vascular (LMAT)$2.3B
Green Thumb Industries (GTBIF)$1.7B